These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 4732567)

  • 1. Enhancement of the pharmacological action of 3,4-dihydroxy-L-phenylalanine(L-dopa) and reduction of dopa decarboxylase activity in rat liver after chronic treatment with L-dopa.
    Tanaka M; Oshima T; Hayashi S; Ishibashi C; Kobayashi S
    Eur J Pharmacol; 1973 Jun; 22(3):360-2. PubMed ID: 4732567
    [No Abstract]   [Full Text] [Related]  

  • 2. Decrease in liver aromatic L-amino-acid decarboxylase produced by chronic administration of L-dopa.
    Dairman W; Christenson JG; Udenfriend S
    Proc Natl Acad Sci U S A; 1971 Sep; 68(9):2117-20. PubMed ID: 5289371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coenzyme--substrate adducts as inhibitors of mouse liver 3,4-dihydroxyphenylalanine decarboxylase.
    Rudd EA; Cunningham WC; Thanassi JW
    J Med Chem; 1979 Mar; 22(3):233-7. PubMed ID: 423204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of pyridoxal phosphate and L-dopapyridoxal phosphate on DOPA decarboxylase activity.
    Tran N
    Experientia; 1972 Sep; 28(9):1021-2. PubMed ID: 4665286
    [No Abstract]   [Full Text] [Related]  

  • 5. Restoration of locomotor activity in mice by low L-DOPA doses after suppression by alpha-methyltyrosine but not by reserpine.
    Ahlenius S; Andén NE; Engel J
    Brain Res; 1973 Nov; 62(1):189-99. PubMed ID: 4358099
    [No Abstract]   [Full Text] [Related]  

  • 6. L-DOPA-chlorpromazine antagonism on running activity in mice.
    Derkach P; Larochelle L; Bieger D; Hornykiewicz O
    Can J Physiol Pharmacol; 1974 Feb; 52(1):114-8. PubMed ID: 4825682
    [No Abstract]   [Full Text] [Related]  

  • 7. The influence of L-DOPA perfusion concentrations and peripheral decarboxylase inhibition on dopa accumulation and decarboxylation in isolated perfused rat brains.
    Horst WD; Bautz G; Renyi E; Spirt N
    Neuropharmacology; 1973 Dec; 12(12):1145-51. PubMed ID: 4782694
    [No Abstract]   [Full Text] [Related]  

  • 8. Behavioral and biochemical effects of L-dopa after peripheral decarboxylase inhibition.
    Butcher LL; Engel J
    Brain Res; 1969 Sep; 15(1):233-42. PubMed ID: 5807767
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition of catechol-O-methyl transferase by L-dopa and decarboxylase inhibitors.
    Baldessarini RJ
    J Pharm Pharmacol; 1972 Jan; 24(1):78-80. PubMed ID: 4401326
    [No Abstract]   [Full Text] [Related]  

  • 10. A comparison of the effects of reversible and irreversible inhibitors of aromatic L-amino acid decarboxylase on the half-life and other pharmacokinetic parameters of oral L-3,4-dihydroxyphenylalanine.
    Huebert ND; Palfreyman MG; Haegele KD
    Drug Metab Dispos; 1983; 11(3):195-200. PubMed ID: 6135575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of chronic L-DOPA administration of catecholamine metabolism in the rat.
    Lancaster J; Sawyer PR; Shepherd DM; Turnbull MJ
    Br J Pharmacol; 1973 Apr; 47(4):838-42. PubMed ID: 4723802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinsonian syndromes. Treatment by association of L-dopa plus decarboxylase inhibitor.
    Gauthier G; Juge O; Birchler A
    Eur Neurol; 1974; 11(3):133-57. PubMed ID: 4839098
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative investigation of inhibitors of extracerebral dopa decarboxylase in man and rats.
    Kuruma I; Bartholini G; Tissot R; Fletscher A
    J Pharm Pharmacol; 1972 Apr; 24(4):289-94. PubMed ID: 4402836
    [No Abstract]   [Full Text] [Related]  

  • 14. Further studies on the behavioural and biochemical interaction between caffeine and L-DOPA.
    Strömberg U; Waldeck B
    J Neural Transm; 1973; 34(4):241-52. PubMed ID: 4359657
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of 3,4-dihydroxyphenylpyruvic acid and its triacetylated derivative on DOPA decarboxylase.
    Lindén IB; Neuvonen PJ; Vapaatalo H
    Acta Pharmacol Toxicol (Copenh); 1982 Sep; 51(3):266-9. PubMed ID: 7136732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of reserpine and prenylamine on the L-dopa turnover in the rat exocrine pancreas.
    Alm P; Ehinger B; Falck B; Nordgren L
    Eur J Pharmacol; 1971 Oct; 16(2):192-200. PubMed ID: 5161258
    [No Abstract]   [Full Text] [Related]  

  • 17. Decrease of the 3,4-dihydroxyphenylalanine (DOPA) decarboxylase activities in human erythrocytes and mouse tissues after administration of DOPA.
    Tate SS; Sweet R; McDowell FH; Meister A
    Proc Natl Acad Sci U S A; 1971 Sep; 68(9):2121-3. PubMed ID: 5289372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-dopa induced changes in central monoamine neurons after peripheral decarboxylase inhibition.
    Butcher L; Engel J; Fuxe K
    J Pharm Pharmacol; 1970 Apr; 22(4):313-6. PubMed ID: 4392579
    [No Abstract]   [Full Text] [Related]  

  • 19. The action L-dopa on sexual behaviour of male rats.
    Da Prada M; Carruba M; Saner A; O'Brien A; Pletscher A
    Brain Res; 1973 Jun; 55(2):383-9. PubMed ID: 4541349
    [No Abstract]   [Full Text] [Related]  

  • 20. Intraventricular injections of L-dopa: the effect on rat locomotor activity and body temperature.
    Reichenberg K; Vetulani J
    Eur J Pharmacol; 1973 Jun; 22(3):376-9. PubMed ID: 4732569
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.